Parallel Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.82M | Buy |
30,078
+1,868
| +7% | +$109K | 0.03% | 318 |
|
|
2025
Q4 | $1.52M | Buy |
28,210
+399
| +1% | +$19.2K | 0.03% | 345 |
|
|
2025
Q3 | $1.25M | Sell |
27,811
-1,522
| -5% | -$71.1K | 0.02% | 370 |
|
|
2025
Q2 | $1.36M | Sell |
29,333
-5,989
| -17% | -$294K | 0.03% | 342 |
|
|
2025
Q1 | $2.15M | Buy |
35,322
+471
| +1% | +$27.5K | 0.05% | 237 |
|
|
2024
Q4 | $1.97M | Buy |
34,851
+829
| +2% | +$46.3K | 0.04% | 256 |
|
|
2024
Q3 | $1.76M | Buy |
34,022
+1,739
| +5% | +$81.6K | 0.04% | 273 |
|
|
2024
Q2 | $1.34M | Sell |
32,283
-273
| -0.8% | -$12.2K | 0.03% | 296 |
|
|
2024
Q1 | $1.77M | Sell |
32,556
-2,630
| -7% | -$134K | 0.05% | 252 |
|
|
2023
Q4 | $1.81M | Sell |
35,186
-13,370
| -28% | -$702K | 0.05% | 222 |
|
|
2023
Q3 | $2.82M | Sell |
48,556
-11,557
| -19% | -$708K | 0.09% | 171 |
|
|
2023
Q2 | $3.84M | Sell |
60,113
-4,068
| -6% | -$273K | 0.12% | 139 |
|
|
2023
Q1 | $4.45M | Sell |
64,181
-2,553
| -4% | -$180K | 0.15% | 122 |
|
|
2022
Q4 | $4.8M | Buy |
66,734
+4,995
| +8% | +$377K | 0.21% | 78 |
|
|
2022
Q3 | $4.39M | Sell |
61,739
-1,007
| -2% | -$73K | 0.2% | 81 |
|
|
2022
Q2 | $4.83M | Buy |
62,746
+5,336
| +9% | +$406K | 0.22% | 73 |
|
|
2022
Q1 | $4.23M | Buy |
57,410
+9,942
| +21% | +$668K | 0.17% | 93 |
|
|
2021
Q4 | $2.96M | Sell |
47,468
-3,957
| -8% | -$232K | 0.11% | 133 |
|
|
2021
Q3 | $3.04M | Buy |
51,425
+999
| +2% | +$65.8K | 0.12% | 126 |
|
|
2021
Q2 | $3.37M | Buy |
50,426
+4,472
| +10% | +$292K | 0.14% | 103 |
|
|
2021
Q1 | $2.9M | Buy |
45,954
+4,658
| +11% | +$290K | 0.14% | 110 |
|
|
2020
Q4 | $2.56M | Sell |
41,296
-1,708
| -4% | -$105K | 0.14% | 113 |
|
|
2020
Q3 | $2.59M | Buy |
43,004
+2,798
| +7% | +$168K | 0.16% | 98 |
|
|
2020
Q2 | $2.36M | Buy |
40,206
+8,431
| +27% | +$504K | 0.15% | 105 |
|
|
2020
Q1 | $1.77M | Buy |
31,775
+3,840
| +14% | +$235K | 0.14% | 109 |
|
|
2019
Q4 | $1.79M | Buy |
27,935
+6,298
| +29% | +$361K | 0.13% | 125 |
|
|
2019
Q3 | $1.1M | Buy |
21,637
+1,082
| +5% | +$50.9K | 0.09% | 161 |
|
|
2019
Q2 | $932K | Sell |
20,555
-183
| -0.9% | -$8.52K | 0.09% | 164 |
|
|
2019
Q1 | $989K | Sell |
20,738
-3,160
| -13% | -$157K | 0.11% | 135 |
|
|
2018
Q4 | $1.24M | Sell |
23,898
-3,516
| -13% | -$189K | 0.17% | 98 |
|
|
2018
Q3 | $1.7M | Buy |
27,414
+6,901
| +34% | +$410K | 0.21% | 86 |
|
|
2018
Q2 | $1.14M | Buy |
20,513
+762
| +4% | +$41.2K | 0.16% | 107 |
|
|
2018
Q1 | $1.25M | Buy |
19,751
+807
| +4% | +$51.9K | 0.2% | 93 |
|
|
2017
Q4 | $1.16M | Sell |
18,944
-2,144
| -10% | -$134K | 0.19% | 92 |
|
|
2017
Q3 | $1.29M | Sell |
21,088
-737
| -3% | -$43K | 0.22% | 87 |
|
|
2017
Q2 | $1.24M | Buy |
21,825
+724
| +3% | +$39.4K | 0.23% | 84 |
|
|
2017
Q1 | $1.16M | Buy |
21,101
+897
| +4% | +$49.2K | 0.23% | 83 |
|
|
2016
Q4 | $1.18M | Buy |
+20,204
| New | +$1.1M | 0.28% | 72 |
|
Other funds holding BMY
VCM
VPM
Parallel Advisors's BMY Position: Q1 2026 in Review
Parallel Advisors increased its Bristol-Myers Squibb (BMY) stake by 6.6% in Q1 2026, buying an estimated $109K and bringing the position to 30,078 shares worth $1.82M. The position accounts for 0.03% of the portfolio, ranked #318.
Parallel Advisors first reported a position in BMY in Q4 2016 and has held it in 38 quarters since. The position peaked at $4.83M in Q2 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Parallel Advisors held 30,078 shares of Bristol-Myers Squibb worth $1.82M as of Q1 2026.
- Parallel Advisors bought 1,868 Bristol-Myers Squibb shares in Q1 2026, an estimated $109K.
- Bristol-Myers Squibb made up 0.03% of Parallel Advisors's portfolio in Q1 2026, its #318 holding.
- Parallel Advisors first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's Bristol-Myers Squibb position peaked at $4.83M in Q2 2022.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.